What is FOXO4-DRI?
FOXO4-DRI is a D-amino acid retro-inverso (DRI) peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 protein that keeps senescent cells (zombie cells) alive. Published mouse studies (Nature 2017) showed that FOXO4-DRI selectively induced apoptosis of senescent cells, improving fitness, coat density, and kidney function. No human clinical trials have been published. Research only; handle with caution.
Mechanism of Action
Competitive disruption of FOXO4–p53 protein-protein interaction in senescent cells; restores p53 nuclear exclusion and mitochondrial apoptotic function specifically in cells with elevated FOXO4 nuclear localization (hallmark of senescent cells)
Target: FOXO4–p53 protein-protein interaction, p53 nuclear localization
Research Indications
Research explores effects on telomere length and cellular senescence
May support age-related hormonal changes
Early research into cognitive preservation with aging
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | Low dose | Per protocol | Varies |
| Standard Dose | Titrated | Per protocol | Varies |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove FOXO4-DRI vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial effects and adaptation period. Monitor for any adverse reactions.
Week 2–4
Primary effects begin to manifest. Adjust dosing as recommended by your provider.
Week 4–8
Main therapeutic effects should be established. Assess progress with your provider.
Week 8+
Evaluate results and determine continuation, cycling, or dose adjustments.
Side Effects & Safety
- Injection site reactions (redness, bruising, mild pain)
- Potential for allergic reaction — discontinue if rash or hives occur
- Individual reactions vary — start at the lowest dose and monitor carefully
- Consult your healthcare provider before use and report any unusual symptoms
FDA Status & Regulatory Info
FOXO4-DRI is a D-amino acid retro-inverso (DRI) peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 protein that keeps senescent cells (zombie cells) alive. Published mouse studies (Nature 2017) showed that FOXO4-DRI selectively induced apoptosis of senescent cells, improving fitness, coat density, and kidney function. No human clinical trials have been published. Research only; handle with caution.
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 28 users report
Positive 97% · Neutral 3% · Negative 0%
Most reported benefits
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 194 days · Based on 26 repeat reporters
Share Your Experience
Rate FOXO4-DRI in the PeptIQ app and help the community make informed decisions.
Research purposes only
This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.